PMID- 33611845 OWN - NLM STAT- MEDLINE DCOM- 20240318 LR - 20240318 IS - 1582-4934 (Electronic) IS - 1582-1838 (Print) IS - 1582-1838 (Linking) VI - 28 IP - 6 DP - 2024 Mar TI - FXR-mediated epigenetic regulation of GLP-1R expression contributes to enhanced incretin effect in diabetes after RYGB. PG - e16339 LID - 10.1111/jcmm.16339 [doi] LID - e16339 AB - In this study, we investigated how Roux-en-Y gastric bypass (RYGB) enhances glucagon-like peptide 1 (GLP-1) response in GK rats and explored the potential link between RYGB-stimulated BAs/FXR signalling and GLP-1R-linked signalling in beta-cells, a key pathway that regulates glucose-stimulated insulin secretion (GSIS). Here we show that RYGB restores GLP-1R expression in GK rat islets. This involves increased total BAs as well as chenodeoxycholic acid (CDCA), leading to FXR activation, increasing FXR binding to the promoter of Glp-1r and enhancing occupancy of histone acetyltransferase steroid receptor coactivator-1 (SRC1), thus increasing histone H3 acetylation at the promoter. These coordinated events bring about increased GLP-1R expression, resulting in greater GLP-1 response in beta-cells. Moreover, ablation of FXR suppressed the stimulatory effects of GLP-1. Thus, this study unravels the crucial role of the BAs/FXR/SRC1 axis-controlled GLP-1R expression in beta-cells, which results in enhanced incretin effect and normalized blood glucose of GK rats after RYGB. CI - (c) 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. FAU - Kong, Xiangchen AU - Kong X AUID- ORCID: 0000-0001-5149-1987 AD - Shenzhen University Diabetes Institute, School of Medicine, Shenzhen University, Shenzhen, China. FAU - Feng, Linxian AU - Feng L AD - Shenzhen University Diabetes Institute, School of Medicine, Shenzhen University, Shenzhen, China. FAU - Yan, Dan AU - Yan D AD - Shenzhen University Diabetes Institute, School of Medicine, Shenzhen University, Shenzhen, China. FAU - Li, Bingfeng AU - Li B AD - Shenzhen University Diabetes Institute, School of Medicine, Shenzhen University, Shenzhen, China. FAU - Yang, Yanhui AU - Yang Y AD - Shenzhen University Diabetes Institute, School of Medicine, Shenzhen University, Shenzhen, China. FAU - Ma, Xiaosong AU - Ma X AD - Shenzhen University Diabetes Institute, School of Medicine, Shenzhen University, Shenzhen, China. LA - eng GR - A2020530/Medical Scientific Research Foundation of Guangdong Province of China/ GR - 81370914, 81670708, 82070845, 82070806, 81400801/National Natural Science Foundation of China/ GR - ZDSYS20190902092903237/Shenzhen Key Laboratory of Metabolism and Cardiovascular Homeostasis/ PT - Journal Article DEP - 20210221 PL - England TA - J Cell Mol Med JT - Journal of cellular and molecular medicine JID - 101083777 RN - 0 (Blood Glucose) RN - 0 (Glp1r protein, rat) RN - 89750-14-1 (Glucagon-Like Peptide 1) RN - 0 (Incretins) RN - 0 (Insulin) RN - 0C5V0MRU6P (farnesoid X-activated receptor) SB - IM MH - Animals MH - Rats MH - Blood Glucose/metabolism MH - *Diabetes Mellitus, Type 2/genetics/surgery MH - Epigenesis, Genetic MH - *Gastric Bypass MH - Glucagon-Like Peptide 1/genetics/metabolism MH - Incretins/metabolism MH - Insulin/metabolism PMC - PMC10941525 OTO - NOTNLM OT - FXR OT - GLP-1 receptor OT - RYGB OT - diabetes OT - epigenetic regulation COIS- The authors confirm that there are no conflicts of interest. EDAT- 2021/02/22 06:00 MHDA- 2024/03/18 06:42 PMCR- 2021/02/21 CRDT- 2021/02/21 20:45 PHST- 2021/01/02 00:00 [revised] PHST- 2020/10/05 00:00 [received] PHST- 2021/01/06 00:00 [accepted] PHST- 2024/03/18 06:42 [medline] PHST- 2021/02/22 06:00 [pubmed] PHST- 2021/02/21 20:45 [entrez] PHST- 2021/02/21 00:00 [pmc-release] AID - JCMM16339 [pii] AID - 10.1111/jcmm.16339 [doi] PST - ppublish SO - J Cell Mol Med. 2024 Mar;28(6):e16339. doi: 10.1111/jcmm.16339. Epub 2021 Feb 21.